Urinary lysophopholipids are increased in diabetic patients with nephropathy.

[1]  H. Jun,et al.  Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice. , 2017, Kidney international.

[2]  M. McCarthy,et al.  The Genetic Landscape of Renal Complications in Type 1 Diabetes. , 2017, Journal of the American Society of Nephrology : JASN.

[3]  Prasenjit Manna,et al.  Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update. , 2016, European journal of pharmacology.

[4]  J. Schanstra,et al.  Increased urinary lysophosphatidic acid in mouse with subtotal nephrectomy: potential involvement in chronic kidney disease , 2016, Journal of Physiology and Biochemistry.

[5]  C. Pollock,et al.  Increased sphingosine 1‐phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy , 2016, Clinical and Experimental Pharmacology and Physiology.

[6]  Guixia Wang,et al.  Metabolomic biomarkers in diabetic kidney diseases--A systematic review. , 2015, Journal of diabetes and its complications.

[7]  J. Ahmad.  Management of diabetic nephropathy: Recent progress and future perspective. , 2015, Diabetes & metabolic syndrome.

[8]  Katalin Susztak,et al.  The Evolving Understanding of the Contribution of Lipid Metabolism to Diabetic Kidney Disease , 2015, Current Diabetes Reports.

[9]  N. Vaziri,et al.  Lipidomics: new insight into kidney disease. , 2015, Advances in clinical chemistry.

[10]  Kerri J Grove,et al.  Diabetic nephropathy induces alterations in the glomerular and tubule lipid profiles1[S] , 2014, Journal of Lipid Research.

[11]  S. Nie,et al.  The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis , 2014, International Urology and Nephrology.

[12]  A. Tokumura,et al.  Presence of bioactive lysophosphatidic acid in renal effluent of rats with unilateral ureteral obstruction. , 2011, Life sciences.

[13]  Julie Klein,et al.  Lysophosphatidic acid-1-receptor targeting agents for fibrosis , 2011, Expert opinion on investigational drugs.

[14]  S. Hadjadj,et al.  Prognostic Value of the Insertion/Deletion Polymorphism of the ACE Gene in Type 2 Diabetic Subjects: Results From the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEP , 2008, Diabetes Care.

[15]  S. Hadjadj,et al.  Prognostic Value of the Insertion/ Deletion polymorphism of Angiotensin I Converting Enzyme gene in type 2 diabetic subjects: results from the DIABHYCAR, DIAB2NEPHROGENE & SURDIAGENE studies. , 2008 .

[16]  J. Chun,et al.  LPA1 receptor activation promotes renal interstitial fibrosis. , 2007, Journal of the American Society of Nephrology : JASN.

[17]  Y. Yatomi,et al.  Lysophospholipase D activity exists in the urine to catalyse the formation of lysophosphatidic acid. , 2006, Nephrology, Dialysis and Transplantation.

[18]  A. Cases,et al.  Dyslipidemia and the progression of renal disease in chronic renal failure patients. , 2005, Kidney international. Supplement.

[19]  J. Pfeilschifter,et al.  Enhanced expression of group IIA secreted phospholipase A2 by elevated glucose levels in cytokine-stimulated rat mesangial cells and in kidneys of diabetic rats. , 2005, Clinical nephrology.

[20]  B. Kasiske,et al.  Effect of lipid reduction on the progression of renal disease: a meta-analysis. , 2001, Kidney international.

[21]  M. Lagarde,et al.  Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. , 2000, The Biochemical journal.

[22]  K. Hruska,et al.  Stimulation of phosphatidylcholine biosynthesis in diabetic hypertrophic kidneys. , 1987, Endocrinology.